Parapres Comp Forte
High-Strength Candesartan 16 mg / Hydrochlorothiazide 12.5 mg Combination for Hypertension
Quick Facts About Parapres Comp Forte
Key Takeaways About Parapres Comp Forte
- High-strength dual-action therapy: Combines 16 mg candesartan with 12.5 mg hydrochlorothiazide, delivering greater blood pressure reduction than either component alone or the lower-strength 8/12.5 mg combination
- Strictly contraindicated in pregnancy: Use during any stage of pregnancy can cause severe foetal injury or death – discontinue immediately if pregnancy is detected
- Electrolyte and renal monitoring essential: Check serum potassium, sodium, creatinine, and eGFR 2–4 weeks after starting and then at least annually; candesartan tends to raise potassium while hydrochlorothiazide tends to lower it
- Take once daily at the same time: Provides smooth 24-hour blood pressure control; morning dosing is preferred to minimise nighttime urination
- Stay well hydrated and protect your skin: The diuretic component increases fluid loss, and long-term hydrochlorothiazide use is linked to a small increased risk of non-melanoma skin cancer – use sun protection
What Is Parapres Comp Forte and What Is It Used For?
Parapres Comp Forte is a once-daily oral tablet containing candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg. It is prescribed for the treatment of essential hypertension (high blood pressure) in adults whose blood pressure is not adequately controlled by candesartan 16 mg alone or by the lower-strength 8/12.5 mg candesartan/hydrochlorothiazide combination.
Parapres Comp Forte belongs to the therapeutic class of fixed-dose combination antihypertensives. The "Forte" designation indicates the higher-strength formulation in the candesartan/hydrochlorothiazide product family; it pairs a doubled candesartan dose (16 mg instead of 8 mg) with the same low-dose diuretic (12.5 mg hydrochlorothiazide) used across the range. This approach is endorsed by major international guidelines, including the 2023 European Society of Cardiology/European Society of Hypertension (ESC/ESH) Guidelines, the American College of Cardiology/American Heart Association (ACC/AHA) Guidelines, and the 2020 International Society of Hypertension (ISH) Global Practice Guidelines, all of which recommend single-pill combination therapy as a preferred strategy for achieving blood pressure targets.
Candesartan cilexetil, the ARB component, is a prodrug that is rapidly hydrolysed to the active compound candesartan during absorption from the gastrointestinal tract. Candesartan selectively and competitively binds to the angiotensin II type 1 (AT1) receptor with exceptionally tight binding affinity and a long dissociation half-life, producing prolonged, near-insurmountable receptor blockade. This prevents angiotensin II from causing arteriolar vasoconstriction, aldosterone secretion, sympathetic activation, and renal sodium retention. At the 16 mg dose used in Parapres Comp Forte, candesartan delivers approximately 80–90% of its maximal blood pressure-lowering effect, which is why this dose is positioned as a robust once-daily ARB backbone.
Hydrochlorothiazide (HCTZ), the diuretic component, acts on the Na+-Cl- cotransporter in the early distal convoluted tubule of the nephron. By blocking this cotransporter, hydrochlorothiazide increases urinary excretion of sodium, chloride, and water, which reduces circulating blood volume in the first weeks of therapy. With continued use, the persistent blood pressure reduction is thought to derive more from a decrease in peripheral vascular resistance than from ongoing volume depletion, a phenomenon attributed to direct vasodilatory effects and long-term adaptations in vascular smooth muscle sodium handling.
The pharmacological rationale for combining these two classes is well established. Thiazide diuretics activate the renin-angiotensin-aldosterone system (RAAS) as a compensatory response to fluid loss, which partially offsets their antihypertensive effect. Adding an ARB such as candesartan blocks this counter-regulatory mechanism at the receptor level, unmasking the full blood pressure-lowering potential of the diuretic. Conversely, the ARB's tendency to raise serum potassium counterbalances the diuretic's potassium-depleting effect, producing a more neutral electrolyte profile than either agent alone. Clinical trials consistently show that the 16/12.5 mg strength of candesartan/hydrochlorothiazide produces approximately 5–7 mmHg greater systolic reduction than candesartan 16 mg monotherapy.
Parapres Comp Forte is used specifically for essential hypertension — sustained blood pressure elevation without an identifiable secondary cause. It is not first-line therapy for newly diagnosed hypertension; rather, it is prescribed as a step-up when monotherapy or the lower-strength combination has failed to achieve the blood pressure target set by your doctor. International guidelines generally recommend an office blood pressure target below 140/90 mmHg for most adults, with tighter targets (below 130/80 mmHg) for patients with diabetes, established cardiovascular disease, or chronic kidney disease.
Hypertension affects an estimated 1.28 billion adults worldwide, according to the World Health Organization (WHO), and is the single largest contributor to global mortality through its role in stroke, ischaemic heart disease, heart failure, and chronic kidney disease. The 2023 ESC/ESH Hypertension Guidelines emphasise that starting treatment with two agents in a single tablet — as with Parapres Comp Forte — improves blood pressure control rates, adherence, and time-to-target compared to sequential single-agent titration.
What Should You Know Before Taking Parapres Comp Forte?
Before starting Parapres Comp Forte, inform your doctor about all medical conditions, particularly kidney or liver disease, diabetes, gout, systemic lupus erythematosus, dehydration, and any allergies — especially to sulfonamide drugs. This medicine must not be used during pregnancy, in severe kidney or liver impairment, or with aliskiren in diabetic patients.
Contraindications
You should not take Parapres Comp Forte if any of the following apply:
- Pregnancy or planning pregnancy: Parapres Comp Forte can cause serious and sometimes fatal foetal injury, particularly during the second and third trimesters. Women of childbearing potential must use effective contraception, and the drug must be stopped immediately if pregnancy is confirmed
- Known hypersensitivity to candesartan, hydrochlorothiazide, or any excipient listed in the section on contents
- Sulfonamide hypersensitivity: Hydrochlorothiazide is a sulfonamide-derived drug, and cross-reactivity may rarely occur in patients with confirmed sulfonamide allergy
- Severe kidney impairment (estimated glomerular filtration rate [eGFR] below 30 mL/min/1.73 m2) or anuria — the kidneys cannot respond adequately to thiazide diuresis
- Severe hepatic impairment, cholestasis, or biliary cirrhosis: Candesartan is partly cleared via bile, and impaired liver function may cause hazardous drug accumulation and an increased risk of hepatic encephalopathy from electrolyte shifts
- Refractory hypokalaemia or hypercalcaemia: Hydrochlorothiazide can deepen these electrolyte disturbances with potentially dangerous consequences
- Symptomatic hyperuricaemia or gout that is not well controlled, because hydrochlorothiazide further raises uric acid levels
- Severe hyponatraemia: The diuretic may further lower sodium and precipitate neurological complications
- Concomitant use of aliskiren in patients with diabetes mellitus or with moderate-to-severe renal impairment (eGFR below 60 mL/min/1.73 m2) — dual RAAS blockade increases the risk of hypotension, hyperkalaemia, and acute kidney injury
Parapres Comp Forte must not be used at any stage of pregnancy. Drugs acting on the renin-angiotensin system have been linked to oligohydramnios (reduced amniotic fluid), foetal renal failure, skull ossification defects, limb contractures, pulmonary hypoplasia, and neonatal death. If you become pregnant while on Parapres Comp Forte, stop the medicine immediately and contact your doctor urgently to switch to a pregnancy-safe antihypertensive such as labetalol, methyldopa, or extended-release nifedipine.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Parapres Comp Forte if you have or have had any of the following:
- Impaired kidney function or renal artery stenosis: Combined ARB and diuretic therapy can worsen kidney function in susceptible patients. Bilateral renal artery stenosis (or unilateral stenosis in a single functioning kidney) is a particular concern — check renal function before starting and within 2–4 weeks afterwards
- Volume or salt depletion: Patients who are dehydrated, on high-dose diuretics, or on a salt-restricted diet may experience pronounced hypotension with the first dose. Correct volume depletion before starting, or start at a lower-strength combination
- Heart failure: Parapres Comp Forte may be used under specialist supervision, but initiation often requires dose adjustments of concurrent heart failure medications and closer monitoring of renal function and potassium
- Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy: Use with caution because excessive blood pressure reduction may impair coronary or cerebral perfusion
- Primary aldosteronism: Patients with this condition typically do not respond to drugs that inhibit the renin-angiotensin system; alternative therapy is preferred
- Diabetes mellitus: Hydrochlorothiazide can worsen glucose tolerance and unmask latent diabetes. Monitor HbA1c and fasting glucose; diabetes treatment may need adjustment. Candesartan is metabolically neutral and may have modest renoprotective effects in diabetic nephropathy
- Gout or hyperuricaemia: Hydrochlorothiazide raises serum uric acid and can trigger gouty flares. Allopurinol or febuxostat dosing may need adjustment
- Systemic lupus erythematosus (SLE): Thiazide diuretics have been reported to exacerbate or activate SLE
- Electrolyte imbalance: Check baseline sodium, potassium, magnesium, calcium, chloride, and uric acid before treatment. Rising doses, intercurrent illness (vomiting, diarrhoea), and concurrent medications can all disturb electrolytes
- Non-melanoma skin cancer risk: Long-term hydrochlorothiazide exposure is associated with a small but measurable increased risk of basal and squamous cell skin cancers; limit UV exposure, use high-SPF sunscreen, and self-examine skin regularly
- Acute myopia and secondary angle-closure glaucoma: Rarely, hydrochlorothiazide can cause an idiosyncratic reaction presenting within hours to weeks as sudden-onset reduced vision or eye pain. Stop the drug immediately and seek ophthalmologic review
- Recent surgery or anaesthesia: Inform your surgeon and anaesthetist — general and spinal anaesthesia can amplify the blood pressure-lowering effect. Some clinicians pause ARBs 24 hours before major surgery
Pregnancy and Breastfeeding
Pregnancy: Parapres Comp Forte is absolutely contraindicated throughout pregnancy. Exposure to angiotensin II receptor blockers during the second and third trimesters is associated with severe foetal and neonatal complications, including renal dysfunction, oligohydramnios, skull hypoplasia, limb contractures, pulmonary hypoplasia, and hypotension. First-trimester data are more limited, but potential harm cannot be excluded. Hydrochlorothiazide during pregnancy can cause foetal or neonatal thrombocytopenia, jaundice, and electrolyte disturbances. Women of childbearing potential must use effective contraception; if pregnancy is planned or confirmed, Parapres Comp Forte must be replaced with a pregnancy-safe agent without delay.
Breastfeeding: Animal data show that candesartan is excreted in milk, and hydrochlorothiazide is known to pass into human breast milk. Potential effects in the nursing infant include hypotension, hyperkalaemia, electrolyte imbalances, and (for hydrochlorothiazide) suppression of lactation at higher doses. Parapres Comp Forte is therefore not recommended during breastfeeding, particularly in the immediate neonatal period or for preterm infants. Alternative antihypertensives compatible with breastfeeding include enalapril, captopril, labetalol, or nifedipine.
Driving and Operating Machinery
Dizziness, fatigue, and blurred vision have been reported with Parapres Comp Forte, particularly at the start of treatment, after dose increases, in hot weather, after alcohol consumption, or in volume-depleted patients. These effects may impair your ability to drive or operate heavy machinery. Assess your individual response before undertaking such activities, and avoid them if you experience any symptoms that might compromise safety.
How Does Parapres Comp Forte Interact with Other Drugs?
Parapres Comp Forte can interact with many medicines, including lithium, NSAIDs, potassium supplements, other antihypertensives, certain diabetes drugs, and anticonvulsants. Both components have distinct interaction profiles, so it is essential to tell your doctor about every prescription drug, over-the-counter medicine, vitamin, mineral supplement, and herbal remedy you are taking.
Interactions with Parapres Comp Forte arise from two main pharmacological pathways. Candesartan primarily interacts with drugs that affect the renin-angiotensin-aldosterone system, potassium balance, or renal haemodynamics. Hydrochlorothiazide interacts with drugs whose effect depends on sodium and potassium balance, extracellular fluid volume, or renal tubular function. Some combinations are contraindicated, others require close monitoring, and a few are simply best avoided when equally effective alternatives exist.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Lithium | Mood stabiliser | Both ARBs and thiazides reduce renal lithium clearance, producing sharp rises in serum lithium levels and risk of neurological toxicity, tremor, and seizures | Generally avoid the combination. If unavoidable, measure lithium levels within 4–5 days of any dose change and every 1–2 weeks thereafter |
| Aliskiren (in diabetes or eGFR <60) | Direct renin inhibitor | Dual RAAS blockade substantially increases the risk of hypotension, hyperkalaemia, and acute kidney injury | Contraindicated in diabetic patients or those with moderate-to-severe renal impairment |
| ACE inhibitors (ramipril, enalapril, lisinopril) | Antihypertensive | Dual RAAS blockade – increased risk of hypotension, syncope, hyperkalaemia, and renal failure without meaningful additional cardiovascular benefit | Avoid combination in routine practice. Reserve for carefully selected specialist cases with close monitoring |
| Potassium supplements and potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) | Electrolyte supplements / Diuretics | Candesartan retains potassium and can cause dangerous hyperkalaemia when combined with other potassium-elevating agents | Avoid routine combination. If required (e.g., heart failure), monitor serum potassium within 1–2 weeks and regularly thereafter |
Moderate Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib) | Anti-inflammatory / Analgesic | Reduce the antihypertensive effect and, when combined with ARB + diuretic, can precipitate acute kidney injury (the classic "triple whammy") | Use lowest effective NSAID dose for shortest duration. Monitor blood pressure and renal function; prefer paracetamol for chronic pain where possible |
| Digoxin | Cardiac glycoside | Diuretic-induced hypokalaemia and hypomagnesaemia increase the risk of digoxin toxicity, ventricular arrhythmias, and conduction block | Monitor serum potassium, magnesium, and digoxin levels regularly; correct deficiencies promptly |
| Metformin and other oral antidiabetics | Antidiabetic | Hydrochlorothiazide can raise blood glucose, reducing glycaemic control. Rare risk of lactic acidosis with metformin if renal function deteriorates | Monitor fasting glucose, HbA1c, and renal function. Adjust antidiabetic therapy as needed |
| Insulin | Antidiabetic (injectable) | Thiazide-induced glucose intolerance may increase insulin requirements, particularly in the first weeks of therapy | Self-monitor blood glucose more frequently after initiation or dose change; discuss dose adjustments with your diabetes team |
| Carbamazepine, oxcarbazepine | Anticonvulsant | Additive risk of symptomatic hyponatraemia (confusion, nausea, seizures), particularly in elderly patients | Check serum sodium 1–2 weeks after initiation and whenever symptoms suggest hyponatraemia |
| Corticosteroids (prednisolone, dexamethasone) and ACTH | Anti-inflammatory / Hormonal | Reduce the antihypertensive effect; increase hydrochlorothiazide-induced potassium loss | Monitor blood pressure and serum potassium; anticipate increased antihypertensive needs during steroid courses |
| Allopurinol | Uricosuric / Xanthine oxidase inhibitor | Increased risk of allopurinol hypersensitivity reactions, particularly in patients with renal impairment induced by combination therapy | Adjust allopurinol dose according to eGFR; watch for rash, eosinophilia, or systemic symptoms |
| Calcium supplements / Vitamin D | Electrolyte / Vitamin | Hydrochlorothiazide reduces urinary calcium excretion, which may cause mild hypercalcaemia with high-dose calcium or vitamin D supplementation | Monitor serum calcium if supplementation is necessary; adjust doses to the lowest effective level |
| Muscle relaxants (curare-type) | Neuromuscular blocker | Hydrochlorothiazide-induced hypokalaemia can prolong neuromuscular blockade during anaesthesia | Inform your anaesthetist; correct potassium before surgery |
| Alcohol | CNS depressant | Enhances blood pressure lowering and orthostatic hypotension; increases the dehydrating effect of hydrochlorothiazide | Limit intake, avoid drinking on an empty stomach, and rise slowly from sitting or lying positions |
This is not an exhaustive list. Herbal products — especially liquorice root, ginseng, yohimbe, and St John's wort — can meaningfully alter the effect of Parapres Comp Forte. Grapefruit juice does not significantly affect candesartan pharmacokinetics, but other food-drug interactions may apply to co-prescribed medicines. Always review your complete medication and supplement list with your doctor or pharmacist at every visit.
What Is the Correct Dosage of Parapres Comp Forte?
The usual adult dose is one tablet of Parapres Comp Forte (candesartan 16 mg / hydrochlorothiazide 12.5 mg) taken once daily, swallowed whole with water, with or without food. It is not intended as initial therapy — patients are typically up-titrated from candesartan monotherapy or a lower-strength combination. Always follow your doctor's prescribed regimen.
Parapres Comp Forte is positioned as a step-up therapy rather than first-line treatment for hypertension. International guidelines recommend starting newly diagnosed patients on a lower-strength single-pill combination (or candesartan monotherapy for milder elevations) and moving to the higher-strength 16/12.5 mg combination only if blood pressure remains above target after 2–4 weeks of adequate adherence. The full antihypertensive effect of any dose change is typically achieved within 4–6 weeks.
Adults
Standard Adult Dosage
One Parapres Comp Forte tablet (16 mg candesartan / 12.5 mg hydrochlorothiazide) taken orally once daily. The tablet should be swallowed whole with a glass of water. It can be taken with or without food. Morning administration is generally preferred to avoid nocturia (night-time urination) caused by the diuretic component, although evening dosing is acceptable if it improves adherence.
If blood pressure remains inadequately controlled on Parapres Comp Forte after 4–6 weeks, your doctor may consider adding a third antihypertensive agent from a different class — typically a dihydropyridine calcium channel blocker such as amlodipine or, for patients with resistant hypertension, a mineralocorticoid receptor antagonist such as spironolactone. Replacing Parapres Comp Forte with the 32/12.5 mg or 32/25 mg candesartan/hydrochlorothiazide combinations (where available) is another option.
Elderly Patients (≥65 years)
Elderly Dosage Considerations
No routine dose adjustment is required solely based on age. However, elderly patients are more susceptible to first-dose hypotension, orthostatic symptoms, dehydration, falls, and electrolyte imbalances. When possible, up-titration from a lower-strength combination is preferred over direct initiation of Parapres Comp Forte in patients over 75 or those who are frail. Renal function and electrolytes should be checked within 1–2 weeks of starting and at least annually thereafter. Encourage adequate fluid intake, especially during warm weather or illness.
Use in Children and Adolescents
Paediatric Information
Parapres Comp Forte is not recommended for use in children or adolescents under 18 years. The safety and efficacy of this fixed-dose combination have not been established in paediatric populations, and the strengths available are not designed for weight-based dosing. Paediatric hypertension is treated with individual components at carefully titrated doses under specialist supervision.
Dose Adjustments for Kidney and Liver Impairment
Renal and Hepatic Considerations
Mild kidney impairment (eGFR 60–89 mL/min/1.73 m2): No dose adjustment is typically required. Monitor renal function and electrolytes within 2–4 weeks of starting.
Moderate kidney impairment (eGFR 30–59 mL/min/1.73 m2): Parapres Comp Forte may be used with caution. Start at the lower-strength combination first where feasible, and monitor kidney function and potassium closely. The diuretic effect of hydrochlorothiazide begins to diminish at this level of renal function.
Severe kidney impairment (eGFR <30 mL/min/1.73 m2) or anuria: Parapres Comp Forte is contraindicated. Thiazide diuretics are generally ineffective at this level of renal function, and loop diuretics should be used instead.
Mild-to-moderate hepatic impairment: Use with caution. A lower candesartan starting dose is recommended before moving to the 16 mg strength.
Severe hepatic impairment, cholestasis, or cirrhosis: Parapres Comp Forte is contraindicated.
Missed Dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose (within about 12 hours), skip the missed dose and resume your regular schedule. Do not take a double dose to compensate for a missed one, as this increases the risk of excessive blood pressure lowering, dizziness, and electrolyte disturbances. Because Parapres Comp Forte provides smooth 24-hour blood pressure control, a single missed dose rarely causes a clinically significant rebound, but consistently missed doses substantially reduce long-term effectiveness and cardiovascular protection.
Overdose
Experience of overdose with Parapres Comp Forte is limited, but severe symptomatic hypotension, tachycardia, bradycardia (from vagal reflex), electrolyte disturbances, and dehydration are the expected features. Treatment is supportive: place the patient supine with legs elevated, give intravenous isotonic saline, and correct electrolyte and acid-base abnormalities. Candesartan is not meaningfully removed by haemodialysis because of its high protein binding, whereas hydrochlorothiazide can be partially removed. Activated charcoal may be considered within one hour of ingestion. If overdose is suspected, seek emergency medical care immediately.
Call your local emergency number or poison control centre immediately if an overdose is suspected. Warning signs include severe dizziness or fainting, very low blood pressure, palpitations, muscle cramps, confusion, fatigue, or markedly reduced urine output. Take the medicine packaging with you so clinicians know exactly what was ingested.
What Are the Side Effects of Parapres Comp Forte?
Like all medicines, Parapres Comp Forte can cause side effects, though not everyone gets them. The most commonly reported adverse effects are dizziness, headache, fatigue, and increased urination. Serious but rare side effects include angioedema, severe allergic reactions, significant electrolyte imbalance, and acute kidney injury. Report swelling of the face, lips, tongue, or throat to emergency services immediately.
The safety profile of Parapres Comp Forte reflects the combined pharmacology of candesartan 16 mg and hydrochlorothiazide 12.5 mg. In pooled clinical trial and post-marketing data, the combination was generally well tolerated, with most adverse events classified as mild to moderate. The hydrochlorothiazide component drives most of the metabolic disturbances (electrolyte shifts, raised uric acid, mildly altered glucose and lipid profiles), while candesartan contributes to hyperkalaemia and, rarely, angioedema. The higher 16 mg candesartan dose may produce slightly more pronounced first-dose hypotension than lower strengths, particularly in volume-depleted patients.
Very Common
- No adverse effects are classified as very common for this combination at the 16/12.5 mg strength; most events occur less frequently. Mild dizziness at treatment onset approaches this frequency in some patient groups (e.g., the very elderly or those previously on monotherapy).
Common
- Dizziness or lightheadedness, particularly on standing up
- Headache
- Fatigue and generalised weakness
- Increased urination (polyuria), especially during the first 1–2 weeks
- Elevated blood uric acid (hyperuricaemia), occasionally triggering gout flares
- Mildly raised fasting blood glucose and HbA1c
- Mildly raised LDL cholesterol and triglycerides
- Low serum potassium (hypokalaemia) – muscle cramps, weakness, palpitations
- Raised serum creatinine and urea (usually modest and reversible)
Uncommon
- Symptomatic hypotension, including orthostatic hypotension
- Nausea, vomiting, or diarrhoea
- Abdominal pain or dyspepsia
- Skin rash, pruritus, or urticaria
- Low serum sodium (hyponatraemia) – confusion, nausea, gait instability
- Low serum magnesium (hypomagnesaemia) – muscle twitching, arrhythmia
- Back pain, muscle cramps, leg cramps
- Sleep disturbance, depressed mood
- Dry mouth, thirst
- Impotence / decreased libido
Rare and Very Rare
- Angioedema (swelling of face, lips, tongue, throat) – seek emergency care immediately
- Severe allergic (anaphylactic) reactions
- Acute kidney injury, acute renal failure, or worsening of pre-existing kidney disease
- Severe hyperkalaemia, particularly with renal impairment or combined RAAS inhibitor therapy
- Pancreatitis – severe abdominal pain radiating to the back with nausea/vomiting
- Photosensitivity reactions – sunburn-like rash after minimal sun exposure
- Hepatitis, jaundice, or raised liver enzymes
- Blood cell abnormalities: leucopenia, neutropenia, thrombocytopenia, haemolytic anaemia
- Interstitial nephritis – fever, rash, and rising creatinine
- Acute angle-closure glaucoma or transient myopia – sudden visual disturbance or eye pain
- Stevens-Johnson syndrome or toxic epidermal necrolysis (very rare, life-threatening skin reactions)
- Acute respiratory toxicity (pneumonitis, non-cardiogenic pulmonary oedema) – reported with hydrochlorothiazide
- Rhabdomyolysis (severe muscle breakdown)
Contact emergency services or attend the nearest emergency department immediately if you experience: swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; a widespread rash with blistering or peeling skin; severe dizziness, fainting, or chest pain; a very fast or irregular heartbeat; sudden reduction in urine output or no urination; signs of pancreatitis (severe abdominal pain radiating to the back); or sudden blurred vision or eye pain.
Long-term hydrochlorothiazide exposure and skin cancer: Pharmacoepidemiological studies, particularly from Denmark, have linked cumulative hydrochlorothiazide use to a modest but dose-dependent increase in the risk of non-melanoma skin cancer (basal cell and squamous cell carcinoma). The risk is thought to be related to the drug's photosensitising properties. If you take Parapres Comp Forte long-term, protect your skin from excessive sun and UV exposure, use broad-spectrum sunscreen with SPF 30 or higher on exposed skin, wear protective clothing and a wide-brimmed hat outdoors, and report any new or changing skin lesions to your doctor without delay. Regular skin self-examinations are advisable.
If you experience any side effect not listed here, or if a listed side effect becomes severe, report it to your doctor, pharmacist, or national pharmacovigilance authority (e.g., the FDA MedWatch programme, EMA EudraVigilance, or equivalent). Spontaneous reports are critical to detecting rare adverse effects and improving drug safety worldwide.
How Should You Store Parapres Comp Forte?
Store Parapres Comp Forte tablets at room temperature below 30°C (86°F) in the original packaging to protect from moisture and light. Keep out of the reach and sight of children. Do not use after the expiry date printed on the carton and blister.
Correct storage preserves the potency and stability of both active ingredients throughout the product's shelf life. Keep the tablets in their original blister strips until immediately before use — the foil protects against light, oxygen, and humidity, all of which can accelerate degradation. Avoid storing medicines in the bathroom cabinet, the kitchen near the stove or sink, or the car, where temperature and humidity can fluctuate widely. A cool, dry drawer or cupboard at standard room temperature is ideal.
Check the expiry date on both the outer carton and the individual blister strip before each use. The expiry date refers to the last day of the indicated month. Discard any tablets that look discoloured, crumbled, cracked, or otherwise altered in appearance. Do not dispose of medicines in household rubbish, sinks, or toilets. Return expired or unused tablets to your pharmacy for environmentally responsible disposal; most countries operate pharmaceutical take-back schemes to prevent drug residues from entering waterways.
Keep Parapres Comp Forte in a secure location out of the reach and sight of children and pets. Accidental ingestion by a child, particularly of multiple tablets, can cause severe hypotension, dehydration, and electrolyte disturbances that require emergency treatment. If accidental ingestion occurs, contact your local poison control centre immediately.
What Does Parapres Comp Forte Contain?
Each Parapres Comp Forte tablet contains two active ingredients – candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg – together with several inactive excipients that support tablet formulation, stability, and absorption.
Active Ingredients
- Candesartan cilexetil 16 mg: An angiotensin II receptor blocker (ARB) that acts as a prodrug, hydrolysed to the active moiety candesartan during absorption. Candesartan selectively and competitively blocks the angiotensin II AT1 receptor with high affinity and slow dissociation, producing sustained vasodilation, reduced aldosterone secretion, and lower blood pressure. The 16 mg dose delivers near-maximal AT1 receptor occupancy.
- Hydrochlorothiazide 12.5 mg: A thiazide diuretic that inhibits the Na+-Cl- cotransporter in the distal convoluted tubule of the nephron. At this low dose, it delivers most of the antihypertensive effect of higher doses with a more favourable metabolic profile, minimising potassium loss, glucose elevation, and lipid changes.
Inactive Ingredients (Excipients)
The typical inactive ingredients in candesartan/hydrochlorothiazide tablets include:
- Lactose monohydrate: A filler/diluent — patients with rare galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should avoid this product
- Maize starch: Used as a filler and disintegrant
- Polyethylene glycol (macrogol 8000): A binder and solubility enhancer
- Hydroxypropyl cellulose: A film-forming agent and binder
- Carmellose calcium (calcium carboxymethylcellulose): A disintegrant that helps the tablet break down in the gastrointestinal tract
- Magnesium stearate: A manufacturing lubricant
- Iron oxide pigments (red and/or yellow): Colouring agents used to differentiate tablet strengths visually
Parapres Comp Forte tablets contain lactose monohydrate. Patients with hereditary galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Patients with mild to moderate lactose intolerance generally tolerate the small quantity per tablet, but should inform their doctor before starting therapy.
Tablet appearance and markings vary by strength and manufacturer. Refer to the package leaflet supplied with your prescription for precise visual identification (shape, colour, and embossed markings).
Frequently Asked Questions About Parapres Comp Forte
Parapres contains only candesartan cilexetil (an angiotensin II receptor blocker) in various strengths (typically 4, 8, 16, and 32 mg). Parapres Comp is the fixed-dose combination containing candesartan 8 mg plus hydrochlorothiazide 12.5 mg, while Parapres Comp Forte is the higher-strength combination containing candesartan 16 mg with the same 12.5 mg hydrochlorothiazide. Treatment typically begins with candesartan monotherapy; Parapres Comp is added if the standard candesartan dose is insufficient, and Parapres Comp Forte is used when further reduction is needed. Your doctor chooses the strength based on your blood pressure response, tolerability, and comorbidities.
Some blood pressure reduction is measurable within a few hours of the first dose – the diuretic effect of hydrochlorothiazide begins within about 2 hours and peaks at 4 hours. However, the full antihypertensive effect of Parapres Comp Forte typically develops over 4 to 6 weeks of consistent daily dosing, as vascular smooth muscle tone, fluid balance, and neurohormonal systems all adjust. Do not expect immediate results; continue taking the medication as prescribed even if you feel well, and do not stop or reduce the dose without consulting your doctor. Hypertension is usually asymptomatic, so "feeling fine" is not a reliable indicator of blood pressure control.
Yes – many patients with resistant hypertension need three or more agents to reach target. Parapres Comp Forte is commonly combined with a dihydropyridine calcium channel blocker (such as amlodipine or lercanidipine), and in more resistant cases with a mineralocorticoid receptor antagonist (such as spironolactone or eplerenone) under specialist supervision. However, Parapres Comp Forte should generally not be combined with ACE inhibitors (ramipril, enalapril, lisinopril) or direct renin inhibitors (aliskiren), as dual blockade of the renin-angiotensin system increases the risk of hypotension, hyperkalaemia, and acute kidney injury without additional cardiovascular benefit. Always review your full medication list with your doctor before starting any new antihypertensive.
First-dose hypotension and orthostatic symptoms are most likely during the first week of therapy, after dose increases, in hot weather, after exercise, or when combined with alcohol. If you feel dizzy, sit or lie down immediately – ideally with your legs elevated – and wait for the feeling to pass before standing again. Rise slowly from lying to sitting, and from sitting to standing. Make sure you are drinking enough water (1.5–2 litres per day in most adults unless your doctor has restricted fluid intake). Avoid alcohol and minimise saunas or hot baths early in therapy. If dizziness is severe, recurrent, accompanied by fainting, or does not settle within a few days, contact your doctor promptly as your dose may need adjustment.
Sustained blood pressure reduction with ARBs and thiazide diuretics reduces the risk of major cardiovascular events. Meta-analyses of randomised trials show that lowering systolic blood pressure by 10 mmHg reduces the risk of stroke by approximately 27%, coronary heart disease events by 17%, heart failure by 28%, and all-cause mortality by 13%. Candesartan specifically has trial evidence in hypertension (SCOPE), heart failure (CHARM), and stroke prevention (SCAST, ACCESS). Hydrochlorothiazide has decades of outcomes evidence from the ALLHAT and other trials. Parapres Comp Forte itself has not been studied as an event-reduction product, but its components provide robust, evidence-based cardiovascular protection when blood pressure is controlled.
Parapres Comp Forte can modestly alter kidney function, particularly in patients who already have chronic kidney disease, are dehydrated, or are taking other drugs that affect the kidneys (notably NSAIDs). The candesartan component dilates the efferent renal arteriole, which can reduce glomerular filtration pressure and cause a small, usually reversible rise in serum creatinine (up to ~30%). A modest creatinine rise within this range is actually expected and reflects successful RAAS blockade; a rise greater than ~30%, a drop in eGFR below 30, or new hyperkalaemia prompts dose reduction or discontinuation. Your doctor will check kidney function and electrolytes before starting, within 2–4 weeks of initiation, and then periodically. Report any significant reduction in urine output, new swelling, or unusual fatigue to your doctor.
Yes – regular physical activity is strongly recommended as part of hypertension management. Aim for at least 150 minutes of moderate-intensity aerobic exercise per week (e.g., brisk walking, cycling, swimming) plus resistance training on two or more days. However, because Parapres Comp Forte increases fluid loss through the diuretic effect, stay well hydrated before, during, and after exercise, especially in hot or humid conditions. Be alert for symptoms of dehydration or excessive blood pressure drop: marked dizziness, muscle cramps, unusual weakness, or a pounding heartbeat. If these occur, stop, rest, rehydrate, and seek medical advice if they persist. Avoid very hot saunas immediately after exercise until you know how you tolerate the medicine.
References
- European Medicines Agency (EMA). Candesartan/Hydrochlorothiazide – Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed January 2026.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006
- World Health Organization (WHO). Hypertension Fact Sheet. Available at: www.who.int. Accessed January 2026.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [NG136]. Updated 2022. Available at: www.nice.org.uk.
- Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357. doi:10.1161/HYPERTENSIONAHA.120.15026
- British National Formulary (BNF). Candesartan cilexetil with hydrochlorothiazide. Available at: bnf.nice.org.uk. Accessed January 2026.
- Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension. 2003;21(5):875-886.
- Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet. 2003;362(9386):759-766.
- Pedersen SA, Gaist D, Schøsler L, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. Journal of the American Academy of Dermatology. 2018;78(4):673-681.e9. doi:10.1016/j.jaad.2017.11.042
- US Food and Drug Administration (FDA). Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. (2013). Related class-level hydrochlorothiazide skin cancer labelling update (2020).
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957-967. doi:10.1016/S0140-6736(15)01225-8
- Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. The Journal of Clinical Hypertension. 2011;13(9):639-643. doi:10.1111/j.1751-7176.2011.00513.x
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in cardiology, clinical pharmacology, and internal medicine. Our team follows the GRADE framework for evidence evaluation and adheres to international clinical guidelines from the WHO, ESC/ESH, ACC/AHA, ISH, and NICE.
All medical claims in this article are supported by peer-reviewed research, systematic reviews, meta-analyses, and internationally recognised clinical guidelines. We prioritise Level 1A evidence wherever available.
iMedic is editorially independent with no pharmaceutical sponsorship, advertising, or commercial influence. Our content exists solely to provide accurate, accessible medical information to patients, caregivers, and the public.
Last medical review: by iMedic Medical Review Board
For more information about our editorial standards, visit our Editorial Standards page. To contact our medical team, visit our Contact page.